Your browser doesn't support javascript.
loading
Development and Preclinical Evaluation of a Copper-64-Labeled Antibody Targeting Glycine-Alanine Dipeptides for PET Imaging of C9orf72-Associated Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.
Shojaei, Monireh; Zhou, Qihui; Palumbo, Giovanna; Schaefer, Rebecca; Kaskinoro, Janne; Vehmaan-Kreula, Pirjo; Bartenstein, Peter; Brendel, Matthias; Edbauer, Dieter; Lindner, Simon.
Afiliación
  • Shojaei M; Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Zhou Q; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.
  • Palumbo G; Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Schaefer R; Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Kaskinoro J; Orion Corporation Orion Pharma, 02200 Espoo, Finland.
  • Vehmaan-Kreula P; Orion Corporation Orion Pharma, 02200 Espoo, Finland.
  • Bartenstein P; Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Brendel M; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.
  • Edbauer D; Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany.
  • Lindner S; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.
ACS Pharmacol Transl Sci ; 7(5): 1404-1414, 2024 May 10.
Article en En | MEDLINE | ID: mdl-38751620
ABSTRACT
Aggregating poly(glycine-alanine) (poly-GA) is derived from the unconventional translation of the pathogenic intronic hexanucleotide repeat expansion in the C9orf72 gene, which is the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Poly-GA accumulates predominantly in neuronal cytoplasmic inclusions unique to C9orf72 ALS/FTD patients. Poly-GA is, therefore, a promising target for PET/CT imaging of FTD/ALS to monitor disease progression and therapeutic interventions. A novel 64Cu-labeled anti-GA antibody (mAb1A12) targeting the poly-GA protein was developed and evaluated in a transgenic mouse model. It was obtained with high radiochemical purity (RCP), radiochemical yield (RCY), and specific activity, and showed high stability in vitro and ex vivo and specifically bound to poly-GA. The affinity of NODAGA-mAb1A12 for poly-GA was not affected by this modification. [64Cu]Cu-NODAGA-mAb1A12 was injected into transgenic mice expressing GFP-(GA)175 in excitatory neurons driven by Camk2a-Cre and in control littermates. PET/CT imaging was performed at 2, 20, and 40 h post-injection (p.i.) and revealed a higher accumulation in the cortex in transgenic mice than in wild-type mice, as reflected by higher standardized uptake value ratios (SUVR) using the cerebellum as the reference region. The organs were isolated for biodistribution and ex vivo autoradiography. Autoradiography revealed a higher cortex-to-cerebellum ratio in the transgenic mice than in the controls. Results from autoradiography were validated by immunohistochemistry and poly-GA immunoassays. Moreover, we confirmed antibody uptake in the CNS in a pharmacokinetic study of the perfused tissues. In summary, [64Cu]Cu-NODAGA-mAb1A12 demonstrated favorable in vitro characteristics and an increased relative binding in poly-GA transgenic mice compared to wild-type mice in vivo. Our results with this first-in-class radiotracer suggested that targeting poly-GA is a promising approach for PET/CT imaging in FTD/ALS.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Pharmacol Transl Sci Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: ACS Pharmacol Transl Sci Año: 2024 Tipo del documento: Article País de afiliación: Alemania